^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Peripheral T-cell Lymphoma |
| Drug: | Aibining (geptanolimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)
Published date:
01/12/2021
Excerpt:
Patients with PD-L1 expression ≥ 50% derived more benefit from geptanolimab treatment compared to < 50% ones (ORR, 53.3% vs. 25.0%, p = 0.013; median PFS 6.2 vs. 1.5 months, p = 0.002).
DOI:
10.1186/s13045-021-01033-1
Trial ID:
